OSLO, Norway, Dec. 12, 2018 /PRNewswire/ --
Targovax ASA (OSE: TRVX), a clinical stage biotechnology
company developing immune activators to target hard-to-treat solid
tumors, announces that CEO Øystein Soug presented today at DNB 9th
Annual Nordic Healthcare Conference in Oslo, Norway.
The presentation provided a corporate overview, highlighting the
Company's two platform technologies including clinical data from
its lead pipeline asset, ONCOS-102, an oncolytic adenovirus, and
the TG cancer vaccine program that targets tumors that express
mutated forms of RAS - mutations known to drive cancer.
Please see the presentation attached. TRVX DNB presentation
The presentation is also available to download at
www.targovax.com.
CONTACT:
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting
(International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/targovax/r/targovax-presents-at-dnb-9th-annual-nordic-healthcare-conference,c2698730
The following files are available for download:
https://mb.cision.com/Public/17093/2698730/b5e0270377c81c80.pdf
|
TRVX DNB
presentation
|